Roche Forecast, price target & analysts
Roche Target price 2025 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Price Target
| Target Price | CHF300.90 |
| Price | CHF256.80 |
| Potential | 17.17% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF300.90. This is 17.17% higher than the current stock price. The highest price target is CHF476.70 85.63% , the lowest is CHF202.00 21.34% . | |
| A rating was issued by 27 analysts: 13 Analysts recommend Roche to buy, 10 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 17.17% . Most analysts recommend the Roche stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
24 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF64.2b . This is 6.12% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF70.7b 16.84% , the lowest is CHF59.5b 1.60% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF60.5b | 3.03% |
|---|---|---|
| 2025 | CHF64.2b | 6.12% |
| 2026 | CHF66.7b | 3.91% |
| 2027 | CHF68.7b | 3.02% |
| 2028 | CHF71.3b | 3.80% |
| 2029 | CHF74.2b | 4.04% |
| 2030 | CHF76.7b | 3.38% |
| 2031 | CHF82.1b | 7.03% |
| 2032 | CHF83.1b | 1.25% |
21 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.3b . This is 23.81% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF28.6b 39.97% , the lowest is CHF21.7b 6.02% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF20.4b | 8.34% |
|---|---|---|
| 2025 | CHF25.3b | 23.81% |
| 2026 | CHF26.5b | 4.67% |
| 2027 | CHF27.3b | 3.19% |
| 2028 | CHF29.5b | 7.95% |
| 2029 | CHF31.3b | 5.95% |
| 2030 | CHF32.9b | 5.33% |
| 2031 | CHF35.7b | 8.44% |
| 2032 | CHF37.3b | 4.46% |
EBITDA Margin
| 2024 | 33.78% | 5.15% |
|---|---|---|
| 2025 | 39.42% | 16.68% |
| 2026 | 39.70% | 0.71% |
| 2027 | 39.77% | 0.18% |
| 2028 | 41.36% | 4.00% |
| 2029 | 42.12% | 1.84% |
| 2030 | 42.92% | 1.90% |
| 2031 | 43.48% | 1.30% |
| 2032 | 44.86% | 3.17% |
22 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF16.6b . This is 100.07% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF18.6b 124.33% , the lowest is CHF13.8b 66.22% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF8.3b | 28.01% |
|---|---|---|
| 2025 | CHF16.6b | 100.07% |
| 2026 | CHF17.6b | 6.26% |
| 2027 | CHF18.5b | 5.27% |
| 2028 | CHF19.3b | 4.44% |
| 2029 | CHF20.4b | 5.24% |
| 2030 | CHF21.3b | 4.50% |
| 2031 | CHF21.3b | 0.09% |
| 2032 | CHF21.5b | 0.95% |
Net Margin
| 2024 | 13.68% | 30.13% |
|---|---|---|
| 2025 | 25.80% | 88.57% |
| 2026 | 26.38% | 2.25% |
| 2027 | 26.96% | 2.20% |
| 2028 | 27.12% | 0.59% |
| 2029 | 27.43% | 1.14% |
| 2030 | 27.73% | 1.09% |
| 2031 | 25.93% | 6.49% |
| 2032 | 25.86% | 0.27% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
22 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF20.82 . This is 101.74% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF23.34 126.16% , the lowest is CHF17.30 67.64% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF10.32 | 27.83% |
|---|---|---|
| 2025 | CHF20.82 | 101.74% |
| 2026 | CHF22.12 | 6.24% |
| 2027 | CHF23.29 | 5.29% |
| 2028 | CHF24.32 | 4.42% |
| 2029 | CHF25.60 | 5.26% |
| 2030 | CHF26.75 | 4.49% |
| 2031 | CHF26.77 | 0.07% |
| 2032 | CHF27.03 | 0.97% |
P/E ratio
| Current | 24.88 | 35.41% |
|---|---|---|
| 2025 | 12.33 | 50.45% |
| 2026 | 11.61 | 5.84% |
| 2027 | 11.03 | 5.00% |
| 2028 | 10.56 | 4.26% |
| 2029 | 10.03 | 5.02% |
| 2030 | 9.60 | 4.29% |
| 2031 | 9.59 | 0.10% |
| 2032 | 9.50 | 0.94% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.58 and an P/S ratio of 3.31 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.79 | 1.04% |
|---|---|---|
| 2025 | 3.58 | 5.66% |
| 2026 | 3.44 | 3.76% |
| 2027 | 3.34 | 2.93% |
| 2028 | 3.22 | 3.66% |
| 2029 | 3.09 | 3.88% |
| 2030 | 2.99 | 3.27% |
| 2031 | 2.80 | 6.57% |
| 2032 | 2.76 | 1.23% |
P/S ratio
| Current | 3.51 | 3.25% |
|---|---|---|
| 2025 | 3.31 | 5.77% |
| 2026 | 3.18 | 3.77% |
| 2027 | 3.09 | 2.93% |
| 2028 | 2.97 | 3.66% |
| 2029 | 2.86 | 3.89% |
| 2030 | 2.77 | 3.27% |
| 2031 | 2.58 | 6.57% |
| 2032 | 2.55 | 1.23% |
Current Roche Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
| HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
| REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Mar 21 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Mar 11 2025 |
| STIFEL EUROPE |
Hold
➜
Hold
|
Unchanged | Mar 02 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Feb 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Apr 06 2025 |
|
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Mar 21 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Mar 11 2025 |
|
Unchanged
STIFEL EUROPE:
Hold
➜
Hold
|
Mar 02 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Feb 02 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
